ES2389670T8 - Uso del PIG para el tratamiento de trastornos asociados a la transmisión sináptica disfuncional - Google Patents

Uso del PIG para el tratamiento de trastornos asociados a la transmisión sináptica disfuncional Download PDF

Info

Publication number
ES2389670T8
ES2389670T8 ES08785844T ES08785844T ES2389670T8 ES 2389670 T8 ES2389670 T8 ES 2389670T8 ES 08785844 T ES08785844 T ES 08785844T ES 08785844 T ES08785844 T ES 08785844T ES 2389670 T8 ES2389670 T8 ES 2389670T8
Authority
ES
Spain
Prior art keywords
pig
treatment
disorders associated
synaptic transmission
dysfunctional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08785844T
Other languages
English (en)
Other versions
ES2389670T3 (es
Inventor
Peter Raymond Flatt
Christian Holscher
Victor Alan Gault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UUTech Ltd
Original Assignee
UUTech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UUTech Ltd filed Critical UUTech Ltd
Application granted granted Critical
Publication of ES2389670T3 publication Critical patent/ES2389670T3/es
Publication of ES2389670T8 publication Critical patent/ES2389670T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES08785844T 2007-09-07 2008-09-08 Uso del PIG para el tratamiento de trastornos asociados a la transmisión sináptica desfuncional Active ES2389670T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0717388.3A GB0717388D0 (en) 2007-09-07 2007-09-07 Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
GB0717388 2007-09-07
PCT/EP2008/007337 WO2009030498A2 (en) 2007-09-07 2008-09-08 Use of gip for the treatment of disorders associated with dysfunctional synaptic transmission

Publications (2)

Publication Number Publication Date
ES2389670T3 ES2389670T3 (es) 2012-10-30
ES2389670T8 true ES2389670T8 (es) 2013-02-08

Family

ID=38640380

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08785844T Active ES2389670T3 (es) 2007-09-07 2008-09-08 Uso del PIG para el tratamiento de trastornos asociados a la transmisión sináptica desfuncional

Country Status (7)

Country Link
US (1) US9062125B2 (es)
EP (1) EP2197475B1 (es)
JP (1) JP5670190B2 (es)
CA (1) CA2698766C (es)
ES (1) ES2389670T3 (es)
GB (1) GB0717388D0 (es)
WO (1) WO2009030498A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
UY33025A (es) 2009-11-13 2011-06-30 Sanofi Aventis Deustschland Gmbh Composicion farmaceutica que comprende un agonista de glp-1 metionina
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201603510D0 (en) * 2016-02-29 2016-04-13 Univ Ulster Compositions for use in the treatment of neurological disease
JP7165496B2 (ja) * 2016-12-26 2022-11-04 花王株式会社 認知機能改善剤
US11319369B2 (en) * 2016-12-26 2022-05-03 Kao Corporation Motor control function improving agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0404124D0 (en) * 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
US7576050B2 (en) * 2001-07-31 2009-08-18 The United States Of America As Represented By The Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
AU2005215136A1 (en) * 2004-02-20 2005-09-01 Novartis Ag DPP-IV inhibitors for treating neurodegeneration and cognitive disorders
EP1937716A2 (en) * 2005-09-08 2008-07-02 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function

Also Published As

Publication number Publication date
US9062125B2 (en) 2015-06-23
WO2009030498A3 (en) 2009-04-23
EP2197475A2 (en) 2010-06-23
ES2389670T3 (es) 2012-10-30
GB0717388D0 (en) 2007-10-17
CA2698766C (en) 2018-07-31
CA2698766A1 (en) 2009-03-12
EP2197475B1 (en) 2012-08-01
US20100204106A1 (en) 2010-08-12
JP5670190B2 (ja) 2015-02-18
JP2010538030A (ja) 2010-12-09
WO2009030498A2 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
ES2389670T8 (es) Uso del PIG para el tratamiento de trastornos asociados a la transmisión sináptica disfuncional
GB0717399D0 (en) Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
BRPI0816209A2 (pt) Artigos absorventes descartáveis do tipo para vestir com subsistemas de ancoramento.
CR11019A (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
BRPI0814405A2 (pt) Aparelho para manutenção de poço com múltiplas finalidades
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BR112012013260A2 (pt) dispositivo usado para o tratamento de rinite através de iluminação bioestimulativa
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
BRPI1008955A2 (pt) Terapia de combinação com derivados de tiocolchicina.
ES2981249T3 (es) Un dispositivo para el tratamiento de la obesidad
ATE537233T1 (de) Beschichtete schleifprodukte mit aggregaten
BR112012011730A2 (pt) tratamentos para distúrbios gastrointestinais
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
ES2606627T8 (es) Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BRPI0910496A2 (pt) aplicação de rifalazil para tratar distúrbios colônicos.
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BRPI0810091A2 (pt) Agentes fugicidas tópicos para tratar distúrbios ungueais
ES1065640Y (es) Aparato para el alargamiento del pene
BRPI0813832A2 (pt) Métodos para tratamento da ansiedade
BR112012002267A2 (pt) compostos para o tratamento de inflamação.
BRPI0909659A2 (pt) tratamento para distúrbios relacionados oculares